Neoplasms

All Conditions

Nervous System Diseases

Musculoskeletal Diseases

Eye Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Adenoma

Glioma

Neurilemmoma

Meningioma

Germinoma

Astrocytoma

Ependymoma

Craniopharyngioma

Adamantinoma

Nerve Sheath Neoplasms

Oligodendroglioma

Optic Nerve Glioma

Solitary Fibrous Tumors

Hemangiopericytoma

Ganglioglioma

Ameloblastoma

Neoplasms, Fibrous Tissue

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Neoplasms, Vascular Tissue

Meningeal Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Bone Neoplasms

Bone Diseases

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Optic Nerve Neoplasms

Peripheral Nervous System Neoplasms

Cranial Nerve Diseases

Optic Nerve Diseases

Peripheral Nervous System Diseases

Neuromuscular Diseases

Neuroendocrine Tumors

Neuroma

Schwannoma

Central Nervous System Germinoma

Neuroepithelioma

Neuroendocrine Tumor

The participants are seen at the outpatient clinic by a physician, physician assistant or trial nurse at standard follow-up times at 2.5, 5, 7.5 and 10 years after radiotherapy.

ProTRAIT

Danielle Eekers

Hiske van der Weide

Inge Compter

Yvonne Klaver

Jaap Zindler

Miranda Kramer

M Kramer

M Kroesen

A Mendez Romero

J Jaspers

I Coremans

The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D image and 3D dose information has been developed and deployed for proton therapy in the Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch proton and a representative group of photon therapy patients.

Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

Time to neurocognitive failure, defined as the time from last radiotherapeutic treatment to the first instance of a measured HVLT-dr of -1.5Z based on the normal data

HVLT- delayed recall decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data

HVLT total recall decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data

TMT a decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data

TMT b decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data

COWA total decline of -1.5Z compared to baseline at 5 years, using the RCI method based on the normal data

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology	NCT04648462	Astrocytoma Ependymoma Ganglioglioma Oligodendroglio... Optic Nerve Gli... Meningioma Nerve Sheath Ne... Adenoma Craniopharyngio... Hemangiopericyt... Germinoma Neurilemmoma	ProTRAIT	18 Years -	Maastricht Radiation Oncology
Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology	NCT04648462	Astrocytoma Ependymoma Ganglioglioma Oligodendroglio... Optic Nerve Gli... Meningioma Nerve Sheath Ne... Adenoma Craniopharyngio... Hemangiopericyt... Germinoma Neurilemmoma	ProTRAIT	18 Years -	Maastricht Radiation Oncology

Spots Global Cancer Trial Database for neurilemmoma

Every month we try and update this database with for neurilemmoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.